Protagenic Therapeutics Warrant
PTIXW
PTIXW was delisted on the 2nd of January, 2026.
3 hedge funds and large institutions have $5.26K invested in Protagenic Therapeutics Warrant in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 0 closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
0.1% more ownership
Funds ownership: 1.16% → 1.26% (+0.1%)
32% less capital invested
Capital invested by funds: $7.79K → $5.26K (-$2.53K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$1.29K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$438 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WAM
1
Warberg Asset Management
Winnetka,
Illinois
| $4.29K | – | – | – |
|
|
JMPWA
2
JP Morgan Private Wealth Advisors
San Francisco,
California
| $600 | +$1.29K | +25,000 | New |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $372 | -$438 | -8,453 | -35% |
|
PTIXW Hedge Fund Activity: Q1 2023 in Review
3 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Protagenic Therapeutics Warrant (PTIXW) for Q1 2023, worth a combined $5.26K — down 32% from $7.79K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new PTIXW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was JP Morgan Private Wealth Advisors, opening a new position worth an estimated $1.29K. The largest seller was Susquehanna International Group, cutting an estimated $438.
- 3 institutional investors held Protagenic Therapeutics Warrant (PTIXW) as of Q1 2023, up from 2 in Q4 2022.
- Funds reported $5.26K of Protagenic Therapeutics Warrant stock for Q1 2023, down 32% quarter-over-quarter.
- 1 fund opened new Protagenic Therapeutics Warrant positions in Q1 2023 and 0 closed out, a net change of +1 holder.
- The largest Protagenic Therapeutics Warrant buyer in Q1 2023 was JP Morgan Private Wealth Advisors, an estimated $1.29K added.
- The largest Protagenic Therapeutics Warrant seller in Q1 2023 was Susquehanna International Group, an estimated $438 sold.
Based on aggregated 13F filings for Q1 2023.